Effect of Fiasp® in Type 1 Diabetes Treatment

Inclusion Criteria

• •Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study (beyond identification of potential participants by searching for patients with type 1 Diabetes diagnosis, Fiasp® prescription information and electronic medical record (EMR) data to identify continuous glucose monitoring (CGM)/flash glucose monitoring (FGM) use
• •Age greater than or equal to 18 years at the time of signing informed consent
• •Switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin. Switch must have occurred greater than or equal to 26 weeks prior to data collection and during 01 September 2017 to 31 August 2018
• •Treated with basal-bolus insulin regimen throughout the 26 weeks prior to Fiasp® initiation
• •Treated with the same basal insulin, i.e. no records of switching the basal insulin, during the 26 weeks prior to Fiasp® initiation or the 26 weeks after Fiasp® initiation
• •Diagnosed with type 1 diabetes for greater than or equal to 12 months prior to Fiasp® initiation
• •Use of CGM/FGM during the 26 weeks prior to Fiasp® initiation and the 26 weeks after Fiasp® initiation
• •Use of the same CGM/FGM device during the full 26-week period after Fiasp® initiation.